Rocket Pharmaceuticals, Inc.
Basic information
- Head office
- 9 Cedarbrook Drive Cranbury, New Jersey 08512 United States
- Chief executive
- Gaurav Shah
- Employees (non-consolidated)
- 202 people
- Employees (consolidated)
- Start date
- 1999-01-01
- End date
Websites
Business
Related companies
—
Network
History
Jonathan joined Rocket as founding Chief Medical Officer in 2016 and has been instrumental in crafting and advancing an industry-leading pipeline of gene therapy programs across AAV cardiology and LV hematology portfolios.
Mr. Boess has served as a director of Inotek / Rocket Pharmaceuticals since January 2016.
Inotek merged with Rocket in January 2018.
Martin joined the company in December 2021 as its founding General Counsel & Chief Compliance Officer.
J&J becoming the top hematology company worldwide in 2024.
Prior to joining Rocket in April 2025, Sarbani was Vice President at Johnson & Johnson Innovative Medicine leading hematology.
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy poster
Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
Rocket’s First FDA Gene Therapy Approval
Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher
News
There is no news.